MetCure Therapeutics

MetCure Therapeutics is a biotechnology company focused on developing first-in-class small molecule therapeutics to overcome chemoresistance and treat metastatic cancers, with a primary emphasis on advanced prostate cancer. The company utilizes a proprietary high-throughput phenotypic screening platform to identify compounds that selectively target therapy-resistant cancer cells and their ability to colonize distant organs like bone. MetCure's pipeline includes three lead drug programs targeting Skp1-Skp2, EED-EZH2, and SLC7A11, all of which are currently in IND-enabling studies. Additionally, the company offers ProFine, a nutraceutical product designed for prostate cancer wellness and biochemically recurrent disease. Founded by academic researchers from Augusta University and Emory University, MetCure aims to address the critical unmet need for patients who have failed standard-of-care chemotherapy.